Enlivex's Allocetra™ Lands FDA RMAT Designation for Knee Osteoarthritis, Paving the Way for Expedited Review

summarizeSummary

Enlivex has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra™ in age-related knee osteoarthritis, supported by positive Phase I/IIa data. The designation enables expedited development and review, and the FDA has requested a Type B meeting to align on the ongoing Phase IIb trial.

check_boxKey Events · Product Development and Regulatory · ENLV

• RMAT Designation Granted

  Based on Phase I/IIa data showing significant improvements in pain and function, the FDA granted RMAT designation to Allocetra™ for age-related symptomatic knee osteoarthritis in patients 64 and older.

• Expedited Regulatory Pathway

  RMAT status brings intensive FDA engagement, potential eligibility for accelerated approval and priority review, and a Type B meeting—requested by the FDA—to discuss the development program.

• Phase IIb Trial Underway

  A randomized, controlled Phase IIb trial is enrolling 182 patients aged 64 and older across the U.S. and EU; top-line data are expected by the end of Q2 2027.

• Large Unmet Medical Need

  Osteoarthritis affects over 32 million Americans, a number projected to reach 78 million by 2040, with limited disease-modifying treatments currently available.

auto_awesomeAnalysis · ENLV · Life Sciences

Securing RMAT designation for Allocetra™ in age-related knee osteoarthritis marks a pivotal regulatory win. It not only validates the Phase I/IIa data but also unlocks a faster development trajectory, including the possibility of accelerated approval. With over 32 million Americans suffering from OA, the move addresses a vast unmet need and bolsters the clinical pipeline story alongside the company's digital asset treasury. The FDA's request for a Type B meeting signals active engagement, which could speed the Phase IIb program toward a pivotal trial.